Prestige Consumer Healthcare (NYSE:PBH) Reaches New 52-Week High – Should You Buy?

by · The Cerbat Gem

Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $82.56 and last traded at $82.27, with a volume of 8579 shares traded. The stock had previously closed at $81.75.

Wall Street Analyst Weigh In

PBH has been the subject of a number of recent analyst reports. Jefferies Financial Group restated a “hold” rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. DA Davidson reiterated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.20.

Get Our Latest Stock Analysis on Prestige Consumer Healthcare

Prestige Consumer Healthcare Price Performance

The company has a quick ratio of 1.90, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The stock has a market cap of $4.05 billion, a price-to-earnings ratio of 20.00, a price-to-earnings-growth ratio of 2.27 and a beta of 0.47. The company’s 50-day moving average is $72.69 and its 200-day moving average is $69.92.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter in the previous year, the company posted $1.07 earnings per share. Prestige Consumer Healthcare’s quarterly revenue was down .9% compared to the same quarter last year. Equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System grew its holdings in Prestige Consumer Healthcare by 77.4% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 25,221 shares of the company’s stock worth $1,830,000 after acquiring an additional 11,000 shares during the period. Lombard Odier Asset Management USA Corp acquired a new stake in Prestige Consumer Healthcare during the 2nd quarter worth $550,000. CANADA LIFE ASSURANCE Co grew its holdings in Prestige Consumer Healthcare by 19.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 47,575 shares of the company’s stock worth $3,453,000 after acquiring an additional 7,715 shares during the period. Sequoia Financial Advisors LLC grew its holdings in Prestige Consumer Healthcare by 12.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock worth $708,000 after acquiring an additional 1,120 shares during the period. Finally, Atria Investments Inc acquired a new stake in Prestige Consumer Healthcare during the 1st quarter worth $1,246,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Recommended Stories